Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05775705 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase changed: Phase 3 → not applicable Show 7 more changesShow less
    • Completed without a posted recruiting period
    • Primary completion date changed from estimate of Aug 1, 2026 to Jul 1, 2026
    • Enrollment target: estimated 25 to confirmed 24
    • Study completion date changed from estimate of Oct 1, 2026 to Aug 1, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: 4 to 3
    • Study description revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The efficacy and safety of L-DEP (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
Trial Details
NCT Number NCT05775705
Lead Sponsor Beijing Friendship Hospital
Conditions
(from sponsor)		 PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Lymphoma
Related terms Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic, Lymphoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov